|

Cisplatin-based induction chemotherapy Clinical Trials

4 actively recruiting trials

Pipeline

Phase 3: 4

Top Sponsors

  • Sun Yat-sen University2
  • Ming-Yuan Chen2

Indications

  • Cancer4
  • Nasopharyngeal Carcinoma3
  • De-escalation Therapy2
  • Nasopharyngeal Carcinoma (NPC)1

Other4 trials

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Phase 3
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
Phase 3
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
Phase 3
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.